Heart drug tested against COVID-19 in High-Risk patients
NCT ID NCT04615949
First seen Apr 26, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This study tested a drug called CardiolRx in 90 hospitalized COVID-19 patients who also had heart disease or risk factors like diabetes, high blood pressure, or obesity. The goal was to see if the drug could lower the chances of death, needing intensive care, or having heart complications. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor Scott & White Health - Temple
Temple, Texas, 76508, United States
-
Complexo Hospitalar de Niteroi- Centro de Pesquisa Clinica
Rio de Janeiro, 24020, Brazil
-
Fundação Faculdade Regional de Medicine de Sao Jose do Rio Preto (SJRP)
São José do Rio Preto, São Paulo, 15090-000, Brazil
-
Fundação Pio XII - Hospital de Amor Barretos
Barretos, São Paulo, 14784-400, Brazil
-
Hospital São Lucas PUCRS
Porto Alegre, Rio Grande do Sul, 90619-900, Brazil
-
IPECC-Instituto de Pesquisa Clínica de Campinas
Campinas, São Paulo, 13060-080, Brazil
-
Instituto do Coração do HCFMUSP
Cerqueira César, São Paulo, 05403-000, Brazil
-
Irmandade Santa Casa de Misericórdia
Porto Alegre, Rio Grande do Sul, Brazil
-
JY Research Institute
Cutler Bay, Florida, 33189, United States
-
Núcleo de Ensino e Pesquisa do Instituto Mário Penna
Conjunto ACM, Santa Maria, 30380-472, Brazil
-
Prairie Education and Research Cooperative
Springfield, Illinois, 62769, United States
-
SVRI- Irmandade de Santa Casa de Misercordia de Santos
Jabaquara, São Paulo, 1409, Brazil
-
Science Valley Research Institute
Campo Largo, Paraná, 83606, Brazil
-
Science Valley Research Institute
Santo André, São Paulo, 1409, Brazil
-
TecSalud
Monterrey, Nuevo León, 64718, Mexico
-
Universidade Estadual de Maringa
Maringá, Paraná, 87020-900, Brazil
-
University of South Florida
Tampa, Florida, 33613, United States
-
University of Texas Health Science Center
San Antonio, Texas, 78229, United States
-
Valleywise Health Medical Center
Phoenix, Arizona, 85008, United States
-
Westchester General Hospital
Miami, Florida, 33155, United States
Conditions
Explore the condition pages connected to this study.